Fluorescent Imaging Demystifies Melanoma
Study validates non-invasive molecular imaging device for point-of-care assessment of suspicious moles
-
By
-
Helen Bristow
-
February 10, 2026
-
Objective:
To evaluate the accuracy of a skin fluorescent imaging (SFI) system for non-invasive molecular testing of atypical pigmented lesions.
Key Findings:
- SFI detected oncogenic activity in 100% of melanoma cases.
- AUC of 0.907 indicates high accuracy in distinguishing lesions associated with melanoma development.
- SFI showed higher sensitivity and specificity compared to dermoscopy.
Interpretation:
SFI provides molecular insights into lesion biology, enhancing decision-making for biopsies and monitoring.
Limitations:
- Study focused on a specific population of atypical lesions; broader applicability needs further validation.
- Subjectivity in visual assessments remains a challenge.
Conclusion:
SFI has the potential to improve melanoma diagnosis and reduce unnecessary biopsies by providing critical biological information.
